Narrow search
Showing 1 - 10 of 877
Cover Image
Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK
Brown, Ruth E.; Hutton, John; Burrell, Anita - In: PharmacoEconomics 19 (2001) 11, pp. 1091-1102
Objective: To compare clinical and economic study data for docetaxel, paclitaxel and vinorelbine in the treatment of … adverse effect rates from phase III clinical trial data for docetaxel, paclitaxel and vinorelbine. Costs were taken from UK …, the incremental cost-utility ratio for docetaxel versus paclitaxel was Lstg 1995 per quality-adjusted life year (QALY …
Persistent link: https://www.econbiz.de/10005590325
Cover Image
Docetaxel: A Pharmacoeconomic Review of its Use in the Treatment of Metastatic Breast Cancer
Lamb, Harriet M.; Wiseman, Lynda R. - In: PharmacoEconomics 14 (1998) 4, pp. 447-459
largely palliative. Recent studies with the taxoids docetaxel and paclitaxel suggest that these agents are effective second … and US healthcare systems. All analyses compared docetaxel with paclitaxel. Since no direct clinical comparisons of these … docetaxel ranged from <0.3% less to 13% more than those of paclitaxel. When utilities were evaluated, docetaxel was associated …
Persistent link: https://www.econbiz.de/10005590405
Cover Image
The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals
Glennie, Judith L.; Torrance, George W.; Baladi, Jean … - In: PharmacoEconomics 15 (1999) 5, pp. 459-468
The first edition of the Guidelines for Economic Evaluation of Pharmaceuticals: Canada was published in November 1994. At that time, the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) was assigned the task of maintaining and regularly updating the Canadian Guidelines....
Persistent link: https://www.econbiz.de/10005449189
Cover Image
Willingness to Pay as a Measure of Health Benefits
Bala, Mohan V.; Mauskopf, Josephine A.; Wood, Lisa L. - In: PharmacoEconomics 15 (1999) 1, pp. 9-18
In this paper, we discuss the use of cost-benefit analysis (CBA) for evaluating new healthcare interventions, present the theoretical basis for the use of willingness to pay as a method for valuing benefits in a CBA and describe how to obtain willingness-to-pay (WTP) measures of health benefits...
Persistent link: https://www.econbiz.de/10005449256
Cover Image
Willingness To Pay: What's in a Name?
Gafni, Amiram - In: PharmacoEconomics 14 (1998) 5, pp. 465-470
Despite renewed enthusiasm for the use of willingness to pay (WTP) in healthcare applications, there are still a lot of objections, resentment and scepticism regarding the desirability and feasibility of this technique. Objections can be classified into different categories: e.g. theoretical,...
Persistent link: https://www.econbiz.de/10005449276
Cover Image
Recent Advances in the Methods of Cost-Benefit Analysis in Healthcare: Matching the Art to the Science
McIntosh, Emma; Donaldson, Cam; Ryan, Mandy - In: PharmacoEconomics 15 (1999) 4, pp. 357-367
This paper outlines recent advances in the methods of cost-benefit analysis (CBA). Economic evaluations in healthcare can be criticised for, amongst other things, the inappropriate use of incremental cost-effectiveness ratios and the reporting of benefits in terms of cost savings, such as...
Persistent link: https://www.econbiz.de/10005590453
Cover Image
Spotlight on Paclitaxel in Non-Small Cell Lung Cancer The full text of this article was published in PharmacoEconomics 2001; 19 (11): 1111-1134.
Plosker, Greg L.; Hurst, Miriam - In: Disease Management and Health Outcomes 10 (2002) 2, pp. 133-136
practice are regimens such as cisplatin or carboplatin combined with paclitaxel, vinorelbine, gemcitabine, docetaxel or … analyses have been conducted on paclitaxel in NSCLC and most have focused on its use in combination with cisplatin. In terms of … clinical efficacy, paclitaxel-cisplatin combinations achieved significantly higher response rates than teniposide plus …
Persistent link: https://www.econbiz.de/10005448865
Cover Image
A Model to Estimate the Cost Benefit of an Occupational Vaccination Programme for Influenza with Influvac(R) in the UK Use of the tradename is for product identification purposes o...
Das Gupta, Roben; Guest, Julian F. - In: PharmacoEconomics 20 (2002) 7, pp. 475-484
Objectives: To model the economic impact of introducing an occupational vaccination programme for influenza with an inactivated influenza subunit vaccine (Influvac(R)) in the UK. Design and setting: Using published sources, a decision tree was constructed which modelled the costs and benefits of...
Persistent link: https://www.econbiz.de/10005448968
Cover Image
Spotlight on Paclitaxel in Ovarian Cancer The full text of this article was published in PharmacoEconomics 2001; 19 (12): 1227-1259.
Young, Melissa; Plosker, Greg L. - In: Disease Management and Health Outcomes 10 (2002) 4, pp. 259-262
Paclitaxel belongs to the group of antitumor agents called the taxanes. Its efficacy in advanced ovarian cancer has … year. Paclitaxel plus carboplatin has similar efficacy to paclitaxel plus cisplatin. There is now consensus that paclitaxel … particular combination employed may vary between institutions and geographical regions, although paclitaxel plus carboplatin is …
Persistent link: https://www.econbiz.de/10005404683
Cover Image
Paclitaxel: A Pharmacoeconomic Review of its Use in Non-Small Cell Lung Cancer
Plosker, Greg L.; Hurst, Miriam - In: PharmacoEconomics 19 (2001) 11, pp. 1111-1134
practice are regimens such as cisplatin or carboplatin combined with paclitaxel, vinorelbine, gemcitabine, docetaxel or … analyses have been conducted on paclitaxel in NSCLC and most have focused on its use in combination with cisplatin. In terms of … clinical efficacy, paclitaxel-cisplatin combinations achieved significantly higher response rates than teniposide plus …
Persistent link: https://www.econbiz.de/10005590339